IEVAX
Price
$14.23
Change
-$0.04 (-0.28%)
Updated
Jul 31 closing price
Net Assets
893.16M
TEDSX
Price
$33.41
Change
-$0.04 (-0.12%)
Updated
Jul 31 closing price
Net Assets
9.45B
Interact to see
Advertisement

IEVAX vs TEDSX

IEVAX vs TEDSX Comparison Chart in %
View a ticker or compare two or three
VS
IEVAX vs. TEDSX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IEVAX is a Buy and TEDSX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TEDSX has more cash in the bank: 9.45B vs. IEVAX (893M). IEVAX pays higher dividends than TEDSX: IEVAX (3.02) vs TEDSX (0.77). IEVAX was incepted earlier than TEDSX: IEVAX (31 years) vs TEDSX (34 years). TEDSX (1.95) is less costly to investors than IEVAX (1.12). IEVAX is a more actively managed with annual turnover of: 63.00 vs. TEDSX (42.28). TEDSX has a lower initial minimum investment than IEVAX: TEDSX (1000) vs IEVAX (2000). IEVAX annual gain was more profitable for investors over the last year : 8.80 vs. TEDSX (8.22). IEVAX return over 5 years is better than : 18.25 vs. TEDSX (6.69).
IEVAXTEDSXIEVAX / TEDSX
Total Expense Ratio1.121.9557%
Annual Report Gross Expense Ratio1.121.9557%
Fund Existence31 years34 years-
Gain YTD8.0616.741120%
Front Load6%N/A-
Min. Initial Investment20001000200%
Min. Initial Investment IRAN/AN/A-
Net Assets893M9.45B9%
Annual Yield % from dividends3.020.77393%
Returns for 1 year8.808.22107%
Returns for 3 years27.7513.00213%
Returns for 5 years18.256.69273%
Returns for 10 years46.8820.90224%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DBOAX25.630.10
+0.39%
BNY Mellon Balanced Opportunity A
DRRIX17.740.02
+0.11%
BNY Mellon Global Real Return - I
VWICX19.170.02
+0.10%
Vanguard International Core Stock Inv
FIDFX37.91-0.11
-0.29%
Fidelity Advisor Mid Cap Value Z
LYFCX17.38-0.49
-2.74%
AlphaCentric Life Sciences & Hlthcare C